{
    "title": "Amgen bets on ChemoCentryx's rare disease drug in $3.7 bln deal",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11080869/Amgen-buy-ChemoCentryx-3-7-billion.html",
    "date": "2022-08-04",
    "keywords": [
        "revenue",
        "drug",
        "chemocentryx",
        "company",
        "immune",
        "enbrel",
        "quarter",
        "share",
        "launch",
        "vasculitis",
        "inc",
        "access",
        "blockbuster",
        "treatment",
        "inflammatory",
        "demand",
        "bone",
        "disease",
        "deal",
        "hand",
        "control",
        "field",
        "spotlight",
        "astrazenecas",
        "purchase",
        "alexion",
        "amgen",
        "competition",
        "therapy",
        "jump",
        "average",
        "profit",
        "forecast",
        "cash",
        "premium",
        "chemocentryxs",
        "offer",
        "price",
        "partner",
        "torch",
        "tavneos",
        "analyst",
        "joseph",
        "year",
        "form",
        "blood",
        "vessel",
        "inflammation",
        "overactivation",
        "system",
        "refinitiv",
        "reporting",
        "khandekar",
        "bengaluru",
        "editing",
        "vinay",
        "dwivedi",
        "aditya",
        "soni",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}